- Home
- CRIS vs DRCT Comparison
CRIS vs DRCT Comparison
Compare CRIS & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | DRCT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 1.9M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRIS | DRCT |
|---|---|---|
| Price | $1.50 | $2.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 270.9K | 9.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,898,000.00 | ★ $34,694,000.00 |
| Revenue This Year | $27.10 | $5.42 |
| Revenue Next Year | $67.74 | $9.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $0.04 |
| 52 Week High | $6.74 | $7.21 |
Technical Indicators
Market Signals| Indicator | CRIS | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 27.16 | 36.81 |
| Support Level | $0.54 | $1.52 |
| Resistance Level | $5.55 | $3.02 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 2.36 | 9.59 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.